Biotechnology Analyst Karnauskas discusses data to be presented at the upcoming ACC Annual Meeting 2023 for Merck’s Sotatercept for treatment of Pulmonary Arterial Hypertension (PAH) on an Analyst/Industry conference call to be held on February 15 at 1 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Aligos announces portfolio reprioritization of NASH, extends cash runway
- Merck price target raised to $118 from $106 at Truist
- Merck says Phase 3 NRG-GY018 trial met primary endpoint of PFS
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Merck sees FY23 adjusted EPS $6.80-$6.95, consensus $7.36